Candriam Luxembourg S.C.A. bought a new position in Mesa Laboratories, Inc. (NASDAQ:MLAB) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 6,000 shares of the medical instruments supplier’s stock, valued at approximately $896,000. Candriam Luxembourg S.C.A. owned about 0.16% of Mesa Laboratories at the end of the most recent quarter.
Other hedge funds also recently bought and sold shares of the company. Voya Investment Management LLC purchased a new position in Mesa Laboratories in the 2nd quarter worth about $221,000. Strs Ohio increased its position in Mesa Laboratories by 5.6% during the 2nd quarter. Strs Ohio now owns 1,900 shares of the medical instruments supplier’s stock valued at $272,000 after purchasing an additional 100 shares during the period. BT Investment Management Ltd purchased a new position in Mesa Laboratories during the 2nd quarter valued at about $277,000. Spark Investment Management LLC purchased a new position in Mesa Laboratories during the 2nd quarter valued at about $300,000. Finally, Sit Investment Associates Inc. purchased a new position in Mesa Laboratories during the 3rd quarter valued at about $314,000. 68.53% of the stock is currently owned by institutional investors.
Shares of Mesa Laboratories, Inc. (MLAB) opened at $133.40 on Monday. Mesa Laboratories, Inc. has a 1-year low of $113.57 and a 1-year high of $169.80. The firm has a market cap of $504.22, a PE ratio of 35.29 and a beta of 0.49. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.86 and a quick ratio of 1.97.
The company also recently declared a quarterly dividend, which will be paid on Friday, December 15th. Stockholders of record on Thursday, November 30th will be issued a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.48%. The ex-dividend date of this dividend is Wednesday, November 29th. Mesa Laboratories’s dividend payout ratio is currently 23.10%.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://sportsperspectives.com/2017/11/20/candriam-luxembourg-s-c-a-takes-position-in-mesa-laboratories-inc-mlab.html.
A number of research analysts have commented on the stock. TheStreet raised shares of Mesa Laboratories from a “c+” rating to a “b” rating in a research report on Monday, November 6th. Zacks Investment Research raised shares of Mesa Laboratories from a “strong sell” rating to a “buy” rating and set a $167.00 target price on the stock in a research report on Tuesday, October 3rd. Finally, BidaskClub downgraded shares of Mesa Laboratories from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 12th.
Mesa Laboratories Profile
Mesa Laboratories, Inc is focused primarily on quality control products and services. The Company operates through four segments: Instruments, Continuous Monitoring, Biological Indicators and Cold Chain. The Instruments Division designs, manufactures and markets quality control instruments and disposable products.
Want to see what other hedge funds are holding MLAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mesa Laboratories, Inc. (NASDAQ:MLAB).
Receive News & Ratings for Mesa Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.